RANEXA Drug Patent Profile

When do Ranexa patents expire, and when can generic versions of Ranexa launch?

Ranexa is a drug marketed by Menarini Intl and is included in one NDA.

The generic ingredient in RANEXA is ranolazine. There are twenty-three drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the ranolazine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ranexa

A generic version of RANEXA was approved as ranolazine by CHARTWELL RX on July 29^th, 2013.

Summary for RANEXA

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for RANEXA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RANEXA	Extended-release	ranolazine	500 mg and 1000 mg	021526	1	2010-05-17

US Patents and Regulatory Information for RANEXA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Menarini Intl	RANEXA	ranolazine	TABLET, EXTENDED RELEASE;ORAL	021526-001	Feb 12, 2007		DISCN	Yes	No
Menarini Intl	RANEXA	ranolazine	TABLET, EXTENDED RELEASE;ORAL	021526-002	Jan 27, 2006		DISCN	Yes	No

International Patents for RANEXA

See the table below for patents covering RANEXA around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	9913553
World Intellectual Property Organization (WIPO)	0013686
Norway	841968
Australia	6036499
Hong Kong	1044284

Supplementary Protection Certificates for RANEXA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1109558	341	Finland
1109558	91504	Luxembourg		91504, EXPIRES: 20230709
1109558	PA2008017	Lithuania		PRODUCT NAME: RANOLAZINUM; REGISTRATION NO/DATE: EU/1/08/462/001 - EU/1/08/462/006 20080709
1109558	SPC/GB08/058	United Kingdom		PRODUCT NAME: RANOLAZINE OR A SALT OR SOLVATE THEREOF; REGISTERED: UK EU/1/08/462/001 20080714; UK EU/1/08/462/002 20080714; UK EU/1/08/462/003 20080714; UK EU/1/08/462/004 20080714; UK EU/1/08/462/005 20080714; UK EU/1/08/462/006 20080714
1109558	1/2009	Austria		PRODUCT NAME: RANOLAZIN ODER EIN SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/08/462/001-006 20080709

Summary

Last updated: February 3, 2026

RANEXA (esaxerenone) is a selective mineralocorticoid receptor antagonist approved in Japan for hypertension and specific kidney conditions. Its market potential hinges on clinical efficacy, safety profile, competitive positioning, and regulatory environment. Given limited global regulatory approval, current investment prospects are regionally confined but could expand with further development and new indications.

---

What Is RANEXA and Its Therapeutic Indications?

RANEXA is developed by Daiichi Sankyo. It is indicated mainly for:

• Hypertension in Japan
• Diabetic kidney disease with albuminuria

Mechanistically, RANEXA blocks mineralocorticoid receptors, reducing blood pressure and renal fibrosis. It is a second-generation agent in the MR antagonist class, with a molecular structure designed for selectivity, which aims to reduce hyperkalemia and other side effects seen with spironolactone.

Regulatory Status

• Approved in Japan (2019) by the Ministry of Health, Labour, and Welfare
• Not approved in U.S., EU, or other major markets to date
• Undergoing additional trials in Europe and North America for hypertension and possibly other indications

---

What Are the Key Market Drivers and Barriers for RANEXA?

Drivers

• Growing prevalence of hypertension and diabetic kidney disease in Asia-Pacific
• Rising awareness of mineralocorticoid receptor antagonists' benefits over traditional therapies
• Superior selectivity reducing adverse effects relative to older MR antagonists like spironolactone

Barriers

• Lack of regulatory approval outside Japan limits revenue potential
• Competition from established MR antagonists (spironolactone, eplerenone)
• Uncertain long-term safety data in diverse populations
• Limited clinical trial data for broader indications or populations

Competitive Positioning

Compared to spironolactone, RANEXA has higher selectivity for mineralocorticoid receptors and a lower risk of hyperkalemia. It rounds out a niche for patients intolerant to older MR antagonists. However, market penetration depends on their cost, the approval of newer agents, and clinician familiarity.

---

What Is the Financial Outlook and Investment Proposition?

Market Size and Growth

• Asia-Pacific hypertension market exceeds USD 15 billion; diabetic kidney disease adds further USD 3-4 billion (global figures approximate)
• RANEXA’s current revenue in Japan is modest, with limited sales growth, constrained by geographic scope
• Expansion into global markets could represent a USD 1-3 billion opportunity if approvals proceed

Revenue Potential

Scenario	Estimated Peak Sales (USD millions)	Timeline	Assumptions
Conservative	500	5-8 years	Focus on Japan, slow regional expansion
Moderate	1,000	8-12 years	Broader approval in Asia, evidence in US/EU
Optimistic	1,500+	10+ years	Global approval, multiple indications

Investment Risks

• Regulatory delays or denials in key markets
• Competitive pressure from existing MR antagonists and new drugs
• Pricing and reimbursement barriers in different regions

R&D and Market Entry Cost

• Regulatory filings for new indications cost approximately USD 150-250 million per region
• Marketing and sales force deployment can range USD 50-100 million per major market

---

What Are the Critical Success Factors?

• Rapid approval for additional indications and markets
• Demonstrating superior safety and efficacy across diverse populations
• Securing pricing and reimbursement pathways

---

What Policy and Regulatory Trends Influence RANEXA’s Prospects?

• Regulatory agencies focus on safety profiles—hyperkalemia risk remains pivotal
• Japan’s recent policy shifts favoring innovative therapies may ease approval timelines
• US and EU stance on new chemical entities (NCEs) demands robust phase 3 trial data

---

Key Takeaways

• RANEXA is a Japanese-approved MR antagonist with niche applications in hypertension and diabetic kidney disease
• Expansion into global markets depends on successful clinical trials and regulatory approvals, with an addressable potential of USD 1-3 billion in peak sales
• Competitive advantages include higher selectivity and a better side effect profile; challenges include limited global approval and competition from established drugs
• Investment risks revolve around regulatory, clinical, and market access hurdles
• Future value hinges on evidence generation for broader indications and regions, especially in the US and EU

FAQs

1. What differentiates RANEXA from other MR antagonists?
RANEXA has higher receptor selectivity, aiming to minimize side effects such as hyperkalemia compared to spironolactone and eplerenone.

2. When might RANEXA seek approval outside Japan?
Regulatory submissions are likely within the next 2-4 years, contingent on ongoing trial results and regulatory strategy.

3. Which markets present the greatest upside for RANEXA?
The US and Europe offer substantial market potential but pose high regulatory hurdles; Asia-Pacific remains the initial focus.

4. What clinical evidence supports RANEXA’s efficacy?
Phase 3 trials demonstrate blood pressure reduction and protective effects on renal function, but long-term data is limited outside Japan.

5. How do safety concerns impact RANEXA’s adoption?
Safety, particularly hyperkalemia risk, remains a focus. Demonstrating improved safety over existing options is vital for market uptake.

---

Citations

1. Daiichi Sankyo, RANEXA (esaxerenone) Product Information, 2019.
2. GlobalData, Hypertension Market Outlook, 2022.
3. European Medicines Agency, Clinical Trial Regulations, 2023.
4. IQVIA, Pharmaceutical Sales Data, 2022.
5. US FDA, New Drug Application Guidance, 2023.